Search

Your search keyword '"Bacon, Tamar E"' showing total 17 results
Start Over Author "Bacon, Tamar E"
17 results on '"Bacon, Tamar E"'

1. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination

Author

Kister, Ilya, primary, Curtin, Ryan, additional, Piquet, Amanda L., additional, Borko, Tyler, additional, Pei, Jinglan, additional, Banbury, Barbara L, additional, Bacon, Tamar E., additional, Kim, Angie, additional, Tuen, Michael, additional, Velmurugu, Yogambigai, additional, Nyovanie, Samantha, additional, Selva, Sean, additional, Samanovic, Marie I., additional, Mulligan, Mark J., additional, Patskovsky, Yury, additional, Priest, Jessica, additional, Cabatingan, Mark, additional, Winger, Ryan C., additional, Krogsgaard, Michelle, additional, and Silverman, Gregg J., additional

Published
2024
Full Text
View/download PDF

3. Increasing age at disability milestones among MS patients in the MSBase Registry

Author

Kister, Ilya, Chamot, Eric, Cutter, Gary, Bacon, Tamar E., Jokubaitis, Vilija G., Hughes, Stella E., Gray, Orla M., Trojano, Maria, Izquierdo, Guillermo, Grand'Maison, Francois, Duquette, Pierre, Lugaresi, Alessandra, Grammond, Pierre, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgio, Oreja-Guevara, Celia, Iuliano, Gerardo, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Rio, Maria Edite, Verheul, Freek, Fiol, Marcela, Van Pesch, Vincent, Slee, Mark, Butzkueven, Helmut, and Herbert, Joseph

Published
2012
Full Text
View/download PDF

4. Hybrid and vaccine‐induced immunity against SAR‐CoV ‐2 in MS patients on different disease‐modifying therapies

Author

Kister, Ilya, primary, Curtin, Ryan, additional, Pei, Jinglan, additional, Perdomo, Katherine, additional, Bacon, Tamar E., additional, Voloshyna, Iryna, additional, Kim, Joseph, additional, Tardio, Ethan, additional, Velmurugu, Yogambigai, additional, Nyovanie, Samantha, additional, Valeria Calderon, Andrea, additional, Dibba, Fatoumatta, additional, Stanzin, Igda, additional, Samanovic, Marie I., additional, Raut, Pranil, additional, Raposo, Catarina, additional, Priest, Jessica, additional, Cabatingan, Mark, additional, Winger, Ryan C., additional, Mulligan, Mark J., additional, Patskovsky, Yury, additional, Silverman, Gregg J., additional, and Krogsgaard, Michelle, additional

Published
2022
Full Text
View/download PDF

5. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Author

Kalincik, Tomas, Kister, Ilya, Bacon, Tamar E, Malpas, Charles B, Sharmin, Sifat, Horakova, Dana, Kubala-Havrdova, Eva, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Bergamaschi, Roberto, Gerlach, Oliver, Sa, Maria J, Kappos, Ludwig, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Van Pesch, Vincent, Shaygannejad, Vahid, Granella, Franco, Spitaleri, Daniele, Iuliano, Gerardo, Maimone, Davide, Prevost, Julie, Soysal, Aysun, Turkoglu, Recai, Ampapa, Radek, Butzkueven, Helmut, Cutter, Gary, for MSBase Study Group, and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire

Subjects
Adult, Male, Multiple Sclerosis, Multiple Sclerosis Severity Score (MSSS), Middle Aged, Severity of Illness Index, Disability Evaluation, Neurology, prognostics, relapse prediction, Recurrence, Disease Progression, Humans, Female, Neurology (clinical), Prospective Studies
Abstract

Background: The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estimate hazards of relapses, confirmed disability accumulation (CDA), and confirmed disability improvement (CDI). The model did not include Multiple Sclerosis Severity Score (MSSS), a disease duration-adjusted ranked score of disability. Objective: To incorporate MSSS into the MSBase prediction model and compare model accuracy with and without MSSS. Methods: The associations between MSSS and relapse, CDA, and CDI were evaluated with marginal proportional hazards models adjusted for three principal components representative of patients’ demographic and clinical characteristics. The model fit with and without MSSS was assessed with penalized r2 and Harrell C. Results: A total of 5866 MS patients were started on disease-modifying therapy during prospective follow-up (age 38.4 ± 10.6 years; 72% female; disease duration 8.5 ± 7.7 years). Including MSSS into the model improved the accuracy of individual prediction of relapses by 31%, of CDA by 23%, and of CDI by 24% (Harrell C) and increased the amount of variance explained for relapses by 49%, for CDI by 11%, and for CDA by 10% as compared with the original model. Conclusion: Addition of a single, readily available metric, MSSS, to the comprehensive MSBase prediction model considerably improved the individual accuracy of prognostics in MS.

Published
2022

6. Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study

Author

Kister, Ilya, primary, Patskovsky, Yury, additional, Curtin, Ryan, additional, Pei, Jinglan, additional, Perdomo, Katherine, additional, Rimler, Zoe, additional, Voloshyna, Iryna, additional, Samanovic, Marie I., additional, Cornelius, Amber R., additional, Velmurugu, Yogambigai, additional, Nyovanie, Samantha, additional, Kim, Joseph J., additional, Tardio, Ethan, additional, Bacon, Tamar E., additional, Zhovtis Ryerson, Lana, additional, Raut, Pranil, additional, Pedotti, Rosetta, additional, Hawker, Kathleen, additional, Raposo, Catarina, additional, Priest, Jessica, additional, Cabatingan, Mark, additional, Winger, Ryan C., additional, Mulligan, Mark J., additional, Krogsgaard, Michelle, additional, and Silverman, Gregg J., additional

Published
2022
Full Text
View/download PDF

7. sj-docx-1-msj-10.1177_13524585221084577 – Supplemental material for Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Author

Kalincik, Tomas, Kister, Ilya, Bacon, Tamar E, Malpas, Charles B, Sharmin, Sifat, Horakova, Dana, Kubala-Havrdova, Eva, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Boz, Cavit, Grand’Maison, Francois, Bergamaschi, Roberto, Gerlach, Oliver, Sa, Maria J, Kappos, Ludwig, Cartechini, Elisabetta, Lechner-Scott, Jeannette, van Pesch, Vincent, Shaygannejad, Vahid, Granella, Franco, Spitaleri, Daniele, Iuliano, Gerardo, Maimone, Davide, Prevost, Julie, Soysal, Aysun, Turkoglu, Recai, Ampapa, Radek, Butzkueven, Helmut, and Cutter, Gary

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221084577 for Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS by Tomas Kalincik, Ilya Kister, Tamar E Bacon, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala-Havrdova, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Cavit Boz, Francois Grand’Maison, Roberto Bergamaschi, Oliver Gerlach, Maria J Sa, Ludwig Kappos, Elisabetta Cartechini, Jeannette Lechner-Scott, Vincent van Pesch, Vahid Shaygannejad, Franco Granella, Daniele Spitaleri, Gerardo Iuliano, Davide Maimone, Julie Prevost, Aysun Soysal, Recai Turkoglu, Radek Ampapa, Helmut Butzkueven and Gary Cutter in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

9. Effectiveness of alternative dose fingolimod for multiple sclerosis

Author

Longbrake, Erin E., primary, Kantor, Daniel, additional, Pawate, Siddharama, additional, Bradshaw, Michael J., additional, von Geldern, Gloria, additional, Chahin, Salim, additional, Cross, Anne H., additional, Parks, Becky J., additional, Rice, Marc, additional, Khoury, Samia J., additional, Yamout, Bassem, additional, Zeineddine, Maya, additional, Russell-Giller, Shira, additional, Caminero-Rodriguez, Ana, additional, Edwards, Keith, additional, Lathi, Ellen, additional, VanderKodde, Danita, additional, Meador, William, additional, Berkovich, Regina, additional, Ge, Lily, additional, Bacon, Tamar E., additional, and Kister, Ilya, additional

Published
2018
Full Text
View/download PDF

11. Increasing age at disability milestones among MS patients in the MSBase Registry.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Kister, Ilya, Chamot, Eric, Cutter, Gary, Bacon, Tamar E, Jokubaitis, Vilija G, Hughes, Stella E, Gray, Orla M, Trojano, Maria, Izquierdo, Guillermo, Grand'Maison, Francois, Duquette, Pierre, Lugaresi, Alessandra, Grammond, Pierre, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgio, Oreja-Guevara, Celia, Iuliano, Gerardo, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Rio, Maria Edite, Verheul, Freek, Fiol, Marcela, Van Pesch, Vincent, Slee, Mark, Butzkueven, Helmut, Herbert, Joseph, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Kister, Ilya, Chamot, Eric, Cutter, Gary, Bacon, Tamar E, Jokubaitis, Vilija G, Hughes, Stella E, Gray, Orla M, Trojano, Maria, Izquierdo, Guillermo, Grand'Maison, Francois, Duquette, Pierre, Lugaresi, Alessandra, Grammond, Pierre, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgio, Oreja-Guevara, Celia, Iuliano, Gerardo, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Rio, Maria Edite, Verheul, Freek, Fiol, Marcela, Van Pesch, Vincent, Slee, Mark, Butzkueven, Helmut, and Herbert, Joseph

Abstract

The more recent MSBase enrollees in each of the mild-to-moderate disability strata were significantly older than earlier enrollees. Possible explanations for this phenomenon are discussed.

Published
2012

15. Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls.

Author

Bacon, Joshua H., Kister, Ilya, Bacon, Tamar E., Pasternak, Eliana, Strauchler, Yael, and Herbert, Joseph

Abstract

There is an urgent need to develop a practical and reliable clinical measure of disease progression in early and mild MS. We hypothesized that a test of sound lateralization, which is exquisitely sensitive to transmission delays in auditory brainstem, could be more useful for detecting processing speed deficits in mildly impaired MS subjects than standard cognitive tasks. Objective. To develop a practical test of sound lateralization for the clinic and to compare performance of MS subjects with variable disability and healthy subjects on Sound Lateralization Test (SLT) and two speed-of-processing tasks. Design. 42 healthy controls and 90 subjects with clinically definite MS, divided into no, mild, and moderate disability strata, were administered the Symbol Digit Modalities Test (SDMT), and 3-second Paced Auditory Serial Addition Test (PASAT). Results. All of the tests showed an overall difference in performance between controls and the three MS groups, but only the SLT measured a significant difference between controls and the no disability group. Conclusion. SLT is rapidly applied, technically simple, and superior to standard processing speed tests for discriminating between healthy controls and nondisabled MS subjects. SLT should be investigated as an outcome measure in early-phase trials and for monitoring early disease progression in the clinic. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

17. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.

Author

Quinn CM, Rajarajan P, Gill AJ, Kopinsky H, Wolf AB, de Camargo CS, Lamb J, Bacon TE, Murray JC, Probasco JC, Galetta KM, Kantor D, Coyle P, Bhise V, Alvarez E, Conway SE, Bhattacharyya S, and Kister I

Subjects
Humans, Female, Male, Retrospective Studies, Middle Aged, Aged, Adult, Treatment Outcome, Multiple Sclerosis drug therapy, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Neoplasms drug therapy
Abstract

Background and Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited. This study aims to assess the rate of MS activity, as well as neurologic and nonneurologic irAEs in persons with MS treated with ICIs for cancer., Methods: Participating sites were invited to this retrospective observational study through the Medical Partnership 4 MS+ listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and history of ICI treatment. The participating neurologist reviewed each chart individually to ensure the inclusion criteria were met. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument., Results: We identified 66 people with MS (median age 66 years, 73% female, 68% not on disease-modifying therapy for MS) who were treated with ICIs for lung cancer (35%), melanoma (21%), or another oncologic indication. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), 2 patients (3%) had relapse or MRI activity, 3 (5%) had neurologic irAEs, and 21 (32%) had nonneurologic irAEs. At the last follow-up, 25 (38%) participants had partial or complete remission of their cancer, while 35 (53%) were deceased., Discussion: In this multi-institutional systematic retrospective study of predominantly older patients with MS, most of whom were not on disease-modifying therapy, MS activity and neurologic irAEs following ICI treatment were rare. These data suggest that preexisting MS should not preclude the use of ICIs for cancer in older patients, but the results may not be generalizable to younger patients with active MS. Prospective studies of ICI safety that enroll younger patients with MS are needed.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results